KULR Technology Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KULR Technology Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.27M | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | $235.6K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $6.9K | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Mar 30, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.17M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $10.74M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $9.83M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.99M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $2.41M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $624.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $830.4K | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $1.27M | May 14, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $771.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.48M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.36M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $1.31M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $436.1K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $603.9K | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $937.4K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $79.0K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($849) | Apr 17, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($61.90M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($17.52M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($23.69M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($19.44M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($11.91M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($2.85M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($1.98M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | ($2.06M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($2.42M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($822.3K) | Apr 17, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($43.00M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($15.23M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($22.41M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($18.29M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($11.51M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($2.34M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($1.98M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | ($2.08M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($2.41M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($823.7K) | Apr 17, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.76M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.74M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.14M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.20M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $1.66M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $289.8K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $502.2K | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $508.1K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $361.2K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $29.4K | Apr 17, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.70M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $15.98M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $18.94M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $16.45M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $11.16M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.49M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.08M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $2.51M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.69M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $398.1K | Apr 17, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($44.88M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($17.34M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($11.97M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($17.35M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($6.81M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($2.73M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($1.19M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | ($1.36M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($1.01M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($594.7K) | Apr 17, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.99M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $573.4K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $266.2K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.68M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $383.3K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $46.1K | Mar 28, 2022 |
| FY2019 | Dec 31, 2019 | $0 | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $16.6K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $51.8K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Apr 17, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.97M | Mar 31, 2026 |
| FY2025 | Dec 24, 2025 | $2.90M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $62.93M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $10.86M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $23.63M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $19.23M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $9.21M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $236.8K | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $451.1K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.22M | Mar 29, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.36M | Mar 31, 2026 |
| FY2025 | Dec 24, 2025 | $0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.50M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $13.05M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.13M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $2.87M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $3.09M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.03M | Mar 19, 2021 |
| FY2016 | Dec 31, 2016 | $237.5K | Mar 30, 2017 |
| FY2016 | Dec 31, 2015 | $3.8K | Mar 30, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.61M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $57.43M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($2.18M) | Mar 31, 2026 |
| FY2023 | Sep 30, 2023 | $1.20M | Apr 12, 2024 |
| FY2024 | Dec 31, 2022 | $10.49M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $16.37M | Apr 12, 2024 |
| FY2022 | Dec 31, 2020 | $6.12M | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | ($797.0K) | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | ($125.1K) | Mar 19, 2021 |
| FY2019 | Dec 31, 2017 | $739.7K | May 14, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($145.71M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($83.81M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($66.29M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($42.59M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($23.16M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($11.25M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($8.40M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | ($6.42M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($4.36M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($1.93M) | Apr 17, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.30M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $29.83M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.19M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $10.33M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $14.86M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $8.88M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $108.9K | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $229.9K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $895.8K | Mar 29, 2019 |
| FY2018 | Dec 31, 2016 | $9.1K | Mar 29, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46.04M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 33.08M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 133.90M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 113.07M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | 104.79M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 89.91M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 81.07M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | 78.71M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | 77.44M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 50.00M | Apr 17, 2018 |